🎉 Thrilled to announce that the Locus team exceeded our fundraising goal of $20,000 for the Crohn's & Colitis Foundation Triangle Take Steps Walk!🚶‍♂️💙 We proudly walked in solidarity to raise #IBDAwareness . Huge thanks to all supporters!

Locus is excited to be a 2024 Triangle Take Steps event sponsor to raise #IBD awareness and support the Crohn's & Colitis Foundation! As a Company, we're exploring how #bacteriophages and #PrecisionMedicine may help treat GI conditions including IBD. Learn more.
takesteps.crohnscolitisfoundation.org/index.cfm?fuse…

Thrilled to be at the 6th Bacteriophage Therapy Summit by Hanson Wade Group today. Looking forward to dialogue around realizing the promise of #bacteriophage tx to address #AMR & other health issues.

Interested in connecting? Email [email protected].

bacteriophage-summit.com

With phage therapy, researchers sharpen another arrow in the quiver against antibiotic resistance. trib.al/WGUEpR5

ICYMI: Learn more about our progress to develop engineered #bacteriophages with the potential to address the epidemic of multi-drug-resistant (MDR) bacterial infections in this Genetic Engineering & Biotechnology News article.

#CRISPR -based therapies have moved from theory to reality, after the recent landmark #FDA approval of the first such treatment - pharmaphorum provides an overview of the treatment and examines other areas CRISPR tools could make major #medical difference.

pharmaphorum.com/rd/innovative-…

#ICYMI last week, Locus received $23.9M in funding from BARDA to advance LBP-EC01, our first-in-class #CRISPR -engineered #bacteriophage therapy, into Part 2 of our Phase 2 ELIMINATE trial for treating #UTIs caused by drug-resistant E. coli.

Read more➡️locus-bio.com/locus-bioscien…

We’re reflecting on a year of progress in our work developing precision medicines to combat bacteria-related diseases. Thanks to our incredible Locus team, partners, investigators and patients for making this progress possible. We look forward to continuing the momentum in 2024!

We're #thankful for the opportunity to advance engineered bacteriophage therapies to address urgent health challenges incl. #antimicrobialresistance & grateful to our talented team & partners for their shared commitment to this mission. Wishing all a happy #Thanksgiving ! #USAAW23

Addressing #AMR demands a shift toward a precision approach. Locus has built a novel CRISPR-engineered #bacteriophage platform & a foundation to bring this new #precisionmedicine forward, incl. robotics & AI tech & a world-class viral vector production facility #USAAW23 #WAAW2023

It's #USAAW23 & #WAAW2023 led by CDC Antimicrobial Resistance & World Health Organization (WHO), dedicated to addressing #AntimicrobialResistance through awareness & support of antibiotic stewardship, global health equity & development of new therapies, like Locus' CRISPR-enhanced  #bacteriophage  precision medicine LBP-EC01.

Thanks Kisaco Research's #PhageFutures  Digital Summit for facilitating important discussions w/ stakeholders working to accelerate translation of bacteriophages into tx. Locus Principal Scientist Robert McKee discussed #manufacturing host selection prophage challenges. #phage #AMR

Attending Kisaco Research's #PhageFutures Digital Summit tomorrow? Don't miss Locus Principal Scientist Robert McKee discussing challenges and strategies around #phage #manufacturing at 10:30 a.m. ET.

kisacoresearch.com/events/phage-f…

We agree-- #infectiousdiseases science is vital, and opportunities like #IDWeek2023 that bring the robust community of clinicians and scientists working to solve these challenges together is a key step toward progress. 👏

By 2050, #superbugs could claim 10M lives/year. Today, we're on Capitol Hill urging Congress to act on #AMR and #PassPASTEUR . This legislation is pivotal in fighting the AMR crisis & fortifying the novel #antimicrobial pipeline. #PASTEURAct
#PASTEURisforPatients #SquashSuperbugs

📆 Mark your calendars as we welcome EBD Group's #BioPharmUSA to the Triangle next week! Join Locus CFO Joe Nixon on Wed, Sept 13, 10 a.m. ET for a dynamic panel on #biopharma partnerships & acquisition strategies, featuring local Research Triangle Park industry leaders informaconnect.com/biopharm-ameri…

Locus is evaluating a clinical-stage investigational treatment for recurrent Urinary Tract Infections ( #UTI ) caused by E. coli bacteria. LBP-EC01 is a precision therapy that kills E. coli while leaving “good” bacteria in your body unaffected. Learn more ➡️ eliminateuti.com

Five years ago #onthisday in Locus history, we moved into our world-class 10,000-square-foot modular cGMP biologics #manufacturing facility, enabling the manufacture of #precisiontherapeutics for clinical development.

Read more ➡ locus-bio.com/platforms/

#DYK : Urinary Tract Infections ( #UTIs ) affect ~150M people annually worldwide? If you are a woman with frequent UTIs, you may qualify to participate in our #clinicaltrial evaluating a new treatment. Learn more ➡️ eliminateuti.com